CSPG4 and melanoma: Moreover, the efficacy and functional persistence of CSPG4-CAR_CD20-CCR T cells could further be amplified through combination with ICB, especially considering its great clinical progress in treatment of advanced melanoma (43) and the encouraging results of combining ICB and adoptive cell therapy observed in preclinical and clinical studies (44–47).